Decoy Therapeutics corrects warrant inducement release, says new warrants exercisable on issuance
Bitget2026/09/22 22:15- Decoy Therapeutics corrected a Sept. 22, 2026 release on its warrant inducement transaction.
- New unregistered warrants for up to 2,368,868 shares are not subject to stockholder approval.
- Warrants will become exercisable immediately upon issuance, not upon any stockholder vote.
- New Warrants will expire five years from the issuance date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data

Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.